Lilly Asia Ventures lillyasiaventures.com

Lilly Asia Ventures (礼来亚洲基金) makes venture capital investments in the life sciences and healthcare sectors in Asia, particularly China. The firm is affiliated with Eli Lilly and Company. Lilly Asia Ventures seeks companies that are going rapidly and emerging as market leaders, as well as those that are developing innovative products with significant impact on medical care in China and around the world. The most typical stage of investment is growth stage, though the firm has also inv...Show all

Lilly Asia Ventures (礼来亚洲基金) makes venture capital investments in the life sciences and healthcare sectors in Asia, particularly China. The firm is affiliated with Eli Lilly and Company. Lilly Asia Ventures seeks companies that are going ...Show all

See All Exits Recent Exits

Phone: +86 21 6340 6188

Fax:

Room 1504, 1 Corporate Avenue
No.222 Hubin Road Huangpu
 Shanghai, 200021
 Shanghai, China

Lilly Asia Ventures - Investments & Acquisitions

Show Real Data Lilly Asia Ventures Investments
See all Recent Investments
Date Company Round Amount Co-investors
2018-08-08EdiGeneSeries A - II$14.51MHG Capital (华盖资本), IDG Capital, and WI Harper Group
2018-07-25AlectorSeries E$133MAbbVie Biotech Ventures, Amgen Ventures, Casdin Capital, Deerfield Management, Dementia Discovery Fund, Euclidean Capital, Federated Equity Funds - Federated Kaufmann Fund, Foresite Capital, Google Ventures, Mission Bay Capital, MRL Ventures, New Leaf Venture Partners, OrbiMed Advisors, Perceptive Advisors, Polaris Partners, and Section 32
2018-06-26Impact TherapeuticsSeries C$30MDecheng Capital
2018-06-06Just BiotherapeuticsSeries B - II$35MARCH Venture Partners, Bank Of China Group Investment Zheshang Capital, Hillhouse Capital Management, Taikang Life Insurance Company, and Temasek Holdings
2018-06-06MetacrineSeries C$65MAlexandria Venture Investments, ARCH Venture Partners, ArrowMark Partners, Deerfield Management, Franklin Templeton Investments, Invus Group, New Enterprise Associates, Polaris Partners, venBIO, Venrock, and Vivo Capital
See all 5 investments